Navigation Links
PharmAthene Progresses Second Generation rPA Anthrax Vaccine
Date:10/31/2011

ANNAPOLIS, Md., Oct. 31, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today further development progress of its second generation rPA anthrax vaccine, SparVax™.  The new vaccine is being developed to provide rapid manufacturing scale-up to respond to a national security emergency.  The Company completed its first cGMP manufacturing run at 1,500 liter commercial scale.  Final analytical testing is ongoing and expected to be completed in December.

"There is widespread acknowledgement of the need for a modern, next-generation anthrax vaccine that can meet the government's needs in the event of an emergency.  A recombinant anthrax vaccine offers the potential for an improved vaccine that is safe, convenient, cost-effective and provides for a significant increase in production yields," remarked Eric I. Richman, President and Chief Executive Officer. "SparVax™ is the first medical countermeasure to successfully transition from early research funded by the National Institutes of Health (NIH) to advanced development in partnership with the Biomedical Advanced Research and Development Authority (BARDA).  SparVax™ represents how our medical countermeasure development program can create products with desired characteristics to meet the needs of our country.  We look forward to continuing a very productive collaboration with our partners in government to address this need and advance this important product."

"This achievement marks the latest in a series of accomplishments for our rPA anthrax vaccine program in 2011," commented Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer. "Earlier this year, we successfully completed the technology transfer of our manufacturing process from the United Kingdom to a United States-based contract manufacturing organization.  Most importantly, PharmAth
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
2. PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
3. Department of Defense Awards $5.7 Million Contract to PharmAthene for Nerve Agent Medical Countermeasure Program
4. PharmAthene Selected for Inclusion in the Russell Global Index and Russell 3000 Index
5. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
6. PharmAthene Completes $6.5 Million Registered Direct Offering
7. PharmAthene Reports First Quarter 2011 Financial and Operating Results
8. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
9. PharmAthene Strengthens Scientific Leadership and Program Management for Future Growth
10. PharmAthene Receives FDA Clearance to Reinitiate Clinical Testing of Valortim®
11. PharmAthene Reports Third Quarter 2010 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... 2015 , ... A newly launched business plan contest will ask startup companies ... in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small ... period of expert mentorship from a senior industry figure drawn from the Pistoia Alliance ...
(Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks ... Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original ... will increase healthcare worker safety and reduce financial costs. , CTI Electronics announces ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... to take part in the first half of “Integrative Biotechnology,” an applied biotechnology ... established in summer 2014, this course combines students from both universities and is ...
(Date:6/30/2015)... Kjell Lindgren , who is making final preparations for ... International Space Station , will be available for live ... 7. Lindgren will participate from the Gagarin Cosmonaut ... The interviews will be preceded at 7:30 a.m. by a ... To schedule an interview, media must contact Stephanie Stoll ...
Breaking Biology Technology:Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2
... Calif., Jan. 12 WaferGen Biosystems,Inc. (OTC ... state-of-the-art gene,expression, genotyping, cell biology and stem ... have successfully demonstrated the,performance of the company,s ... of the platform,s ongoing alpha testing program. ...
... -- Simcere Pharmaceutical Group,(NYSE: SCR ), ... and manufacturer of the patented anti-cancer biotech product,Endu ... preliminary revenue,and earnings for the full year of ... preliminary data for the fourth quarter, Simcere expects ...
... PHOENIX, Jan. 9 Houlihan Smith & Co., ... non-control equity investment,into Sottera, Inc. d/b/a NJOY, as ... Chairman of Houlihan Smith & Company, Inc. ... Reginald McGaugh.,Terms were not disclosed. , ...
Cached Biology Technology:WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 2WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 3WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 4WaferGen's SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program 5Simcere Pharmaceutical Group Announces Preliminary Full Year Revenue and Earnings 2Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc. 2
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, ... devices with specialties in single use solutions, headquartered in ... MedConx, Inc. (a California corporation with ... San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility in ...
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2TAKE Solutions Awarded Patent By USPTO 2
... is the world,s largest chemical company. At its headquarters ... two steam crackers, two gas and steam turbine power ... helping make information and data on every plant on ... assembly coordinators, safety experts and asset managers. A virtual ...
... 2, 2012) A Central African protected area that straddles ... been named a World Heritage Site by the United Nations ... Called ... acronym TNS) the site consists of a 25,000 km2 (10,000 ...
... but the prevalence of heart disease in pregnant mothers has ... until they are older. These women, who are generally less ... cholesterol levels and are at greater risk of heart disease ... the heart typically functions better during pregnancy due to a ...
Cached Biology News:Virtual plant planning, retrofitting and maintenance 2UN protects 'wild heart' of Central Africa 2UN protects 'wild heart' of Central Africa 3UCLA study looks at why heart attacks cause so much more damage in late pregnancy 2
... Science Smart Minis 300V power supply (Cat. ... higher voltage, sufficient for SDS-PAGE, and native ... two pairs of terminator pairs can be ... designed for individuals to have his/her own ...
... is a dedicated imaging system for fluorescent ... with a very sensitive camera to detect ... in tumor research, infectious disease research, gene ... NightOWL is the only imager with a ...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
... polyclonal antibody raised against a ... Immunogen: SF3B2 (NP_006833, ... partial recombinant protein with GST ... Number: NM_006842 ...
Biology Products: